Leo Cancer Care opts for Device Technologies as exclusive distributor for Australia, New Zealand and South East Asian region

Singapore, 30 May, 2025 – Innovative medical device manufacturer, Leo Cancer Care, has nominated renowned medical technology company, Device Technologies, to introduce and roll out its highly-anticipated upright radiotherapy solution to medical institutions across Australia, New Zealand and South East Asia.

The innovative device, an upright patient positioning system and CT scanner, is working its way through regulatory approvals, beginning with its 501(k) Pending status with the FDA in the U.S.. The technology, which was founded in Australia, is widely expected to transform particle radiation therapy by improving the treatment experience for patients and creating mass efficiencies for the medical industry in Australia, New Zealand and South East Asia in the near future.

Stephen Towe, Chief Executive Officer of Leo Cancer Care, said: “Collaborating with Device Technologies is the next step on our journey that began nearly 10 years ago. We’ve always felt that upright should be the future for patient care in radiotherapy. We’re excited about our capability to transform the industry and benefit both patients and medical professionals through a range of never-seen-before innovations, and know that Device Technologies is the right distributor to help us achieve this on a large scale in this region.

Nat McLay, Managing Director of Device Technologies Asia, said: “We are excited about this new relationship with Leo Cancer Care, which is set to improve patient outcomes through innovative medical technology. Leo Cancer Care is redefining the radiotherapy experience with a unique, patient-centric approach, and we are proud to support the introduction of their upright treatment technology into our regions. This collaboration strengthens our oncology portfolio and reinforces our commitment to bringing transformative technologies to clinicians and their patients.”